Cancer risk in HIV-infected individuals on HAART is largely attributed to oncogenic infections and state of immunocompetence

M Vogel, O Friedrich, G Lüchters, B Holleczek, J C Wasmuth, E Anadol, C Schwarze-Zander, J Nattermann, J Oldenburg, T Sauerbruch, J K Rockstroh, Ulrich Spengler, M Vogel, O Friedrich, G Lüchters, B Holleczek, J C Wasmuth, E Anadol, C Schwarze-Zander, J Nattermann, J Oldenburg, T Sauerbruch, J K Rockstroh, Ulrich Spengler

Abstract

Objectives: To estimate the cancer risk of HIV-infected patients in the HAART era with respect to a general reference population and to determine risk factors for malignancy.

Methods: Long term (1996-2009) cancer incidence of the Bonn single centre HIV cohort was compared to the incidence of the reference population of Saarland using standardized incidence ratios (SIR). Poisson regression analysis was used to identify predictors of cancer risk.

Results: 1,476 patients entered the cohort, enabling 8,772 person years of observation. 121 tumours in 114 patients, 7 in-situ and 114 invasive cancers, were identified. Malignancies associated with infectious agents such as Kaposi sarcoma (SIRs: male: 5,683; female: 277), non-Hodgkin lymphoma (SIRs male: 35; female: 18), anal cancer (SIRs male: 88; female: 115) as well a cervical carcinoma (SIR female: 4) and Hodgkin?s disease (SIR male: 39) and liver cancer (SIR male: 18) were substantially more frequent in HIV-infected patients than in the general population (p< 0.001, each), whereas all other types of cancer were not increased. Poisson regression identified HAART (incidence rate ratio IRR (95% CI): 0.28 (0.19-0.41), p<0.001), CD4 count (IRR per 100 cells/μl increase: 0.66 (0.57-0.76), p<0.001), hepatitis B (IRR: 2.15 (1.10-4.20), p = 0.046) and age (IRR per 10 year increase: 1.23 (1.03 - 1.46), p = 0.023) as independent predictors for the occurrence of any type of cancer.

Conclusions: HAART and preserved CD4 cells preferentially reduce the risk of malignancies associated with oncogenic infections.

Figures

Figure 1
Figure 1
a-c. Incidence rate ratios male patients, stratified according to HIV- and CD4-status: a) all cancer, b) infection related, c) cancer unrelated to infectious diseases.

References

    1. Mocroft A, Ledergerber B, Katlama C. et al.Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet. 2003;362:22–9. doi: 10.1016/S0140-6736(03)13802-0.
    1. Friis-Moller N, Sabin CA, Weber R. et al.Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med. 2003;349:1993–2003.
    1. Goulet JL, Fultz SL, Rimland D. et al.Aging and infectious diseases: do patterns of comorbidity vary by HIV status, age, and HIV severity? Clin Infect Dis. 2007;45:1593–601. doi: 10.1086/523577.
    1. Rosenthal E, Pialoux G, Bernard N. et al.Liver-related mortality in human-immunodeficiency-virus-infected patients between 1995 and 2003 in the French GERMIVIC Joint Study Group Network (MORTAVIC 2003 Study) J Viral Hepat. 2007;14:183–8. doi: 10.1111/j.1365-2893.2006.00791.x.
    1. Castro K, Ward J, Slutsker L, Buehler J, Jaffe H, Berkelman R. 1993 Revised Classification System for HIV Infection and Expanded Surveillance Case Definition for AIDS among Adolescents and Adults. Morbidity and Mortality Weekly Report. 1992;41:1.
    1. Engels EA, Pfeiffer RM, Goedert JJ. et al.Trends in cancer risk among people with AIDS in the United States 1980-2002. AlDs. 2006;20:1645–54.
    1. Patel P, Hanson DL, Sullivan PS. et al.Incidence of types of cancer among HIV-infected persons compared with the general population in the United States, 1992-2003. Ann Intern Med. 2008;148:728–36.
    1. Shiels MS, Cole SR, Kirk GD, Poole C. A Meta-Analysis of the Incidence of Non-AIDS Cancers in HIV-Infected Individuals. J Acquir Immune Defic Syndr. 2009.
    1. Katalinic A, Bertz J, Haberland J, Wolf U. Incidence and Trends. Berlin: Association of Population-based Cancer Registries in Germany and Robert Koch Institute; 2008. Cancer in Germany 2003-2004.
    1. Haberland J, Bertz J, Gorsch B, Schon D. Cancer incidence estimates for Germany via log-linear models. Gesundheitswesen. 2001;63:556–60. doi: 10.1055/s-2001-16687.
    1. Boyle P, Parkin D. Cancer registration: principles and methods. Statistical methods for registries. IARC Sci Publ. 1991;95:126–58.
    1. R Development Core Team. R: A Language and Environment for Statistical Computing. Vienna: R Foundation for Statistical Computing; 2009.
    1. Guiguet M, Boue F, Cadranel J, Lang JM, Rosenthal E, Costagliola D. Effect of immunodeficiency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDH-ANRS CO4): a prospective cohort study. Lancet Oncol. 2009.
    1. Albrecht H, Helm EB, Plettenberg A. et al.Kaposi's sarcoma in HIV infected women in Germany: more evidence for sexual transmission. A report of 10 cases and review of the literature. Genitourin Med. 1994;70:394–8.
    1. Laney AS, Cannon MJ, Jaffe HW. et al.Human her-pesvirus 8 presence and viral load are associated with the progression of AIDS-associated Kaposi's sarcoma. AIDS. 2007;21:1541–5. doi: 10.1097/QAD.0b013e3282202b7d.
    1. Grulich AE, van Leeuwen MT, Falster MO, Vajdic CM. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet. 2007;370:59–67. doi: 10.1016/S0140-6736(07)61050-2.
    1. Powles T, Robinson D, Stebbing J. et al.Highly active antiretroviral therapy and the incidence of non-AIDS-defining cancers in people with HIV infection. J Clin Oncol. 2009;27:884–90. doi: 10.1200/JCO.2008.19.6626.
    1. Bruyand M, Thiebaut R, Lawson-Ayayi S. et al.Role of uncontrolled HIV RNA level and immunodeficiency in the occurrence of malignancy in HIV-infected patients during the combination antiretroviral therapy era: Agence Nationale de Recherche sur le Sida (ANRS) CO3 Aquitaine Cohort. Clin Infect Dis. 2009;49:1109–16. doi: 10.1086/605594.
    1. Clifford GM, Polesel J, Rickenbach M. et al.Cancer risk in the Swiss HIV Cohort Study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy. J Natl Cancer Inst. 2005;97:425–32. doi: 10.1093/jnci/dji072.
    1. Clumeck N, Pozniak A, Raffi F, EACS Executive Committee. Guidelines on the Clinical Management and Treatment of HIV Infected Adults in Europe. EACS European AIDS Clinical Society. Paris, France. accessed December 8th, 2009.
    1. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. 2009. pp. 1–161. accessed December 8th.
    1. Lackner AA, Mohan M, Veazey RS. The gastrointestinal tract and AIDS pathogenesis. Gastroenterology. 2009;136:1965–78.

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere